Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878478 | 1.00 | KMO (0.46) | KMOCYP17A1EGLN2HDAC3HDAC4 | |
| SCHEMBL22121890 | 0.91 | KMO (0.51) | KMOL3MBTL1 | |
| SCHEMBL1556579 | 0.86 | HRH4 (0.42) | KMO | |
| SCHEMBL25147466 | 0.86 | PIK3CD (0.41) | KMO | |
| SCHEMBL1556567 | 0.79 | KMO (0.36) | KMO | |
| SCHEMBL28955995 | 0.74 | KMO (0.60) | KMOCYP17A1EGLN2HDAC3HDAC4 | |
| SCHEMBL6119719 | 0.73 | KMO (0.42) | KMOCYP17A1 | |
| SCHEMBL1661899 | 0.73 | KMO (0.46) | KMOCYP17A1EGLN2HDAC3HDAC4 | |
| SCHEMBL15446373 | 0.73 | KMO (0.42) | KMOCYP17A1EGLN2HDAC3HDAC4 | |
| SCHEMBL8817437 | 0.73 | KMO (0.42) | KMOCYP17A1EGLN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850189-A | Method for continuous flow synthesis of 5-bromo-6-cyclopropylpyrimidine-4-ol | 武汉海特生物创新医药研究有限公司 | 2023-03-28 | — | — | CN | claimed |
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4741387-A1 | CRYSTAL FORM OF BIPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4543890-A1 | USP1 INHIBITORS AND USES THEREOF | Forma Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119836421-A | USP1 inhibitors and uses thereof | 森韬医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119731178-A | USP1 inhibitors and uses thereof | 福马治疗有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025007777-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| WO-2015160654-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| WO-2015017335-A1 | AZAINDOLE COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| WO-2000063176-A2 | DISUBSTITUTED PYRIDINES AND PYRIMIDINES AS HERBICIDES AND FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-26 | — | — | WO | disclosed |
| EP-0185778-A1 | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4588711-A | Insecticidal phosphorus derivatives of 6-cycloalkyl-4-pyrimidinols | THE DOW CHEMICAL COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4489068-A | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | KMO 2727/4885CYP17A1 26/4885EGLN2 1331/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | KMO 1682/4885CYP17A1 857/4885EGLN2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.